Login / Signup

One-Year Comparative Effectiveness of Upadacitinib Versus Tofacitinib For Ulcerative Colitis: A Multicenter Cohort Study.

Rahul S DalalGovind KallumkalHeidy J CabralEdward L BarnesJessica R Allegretti
Published in: The American journal of gastroenterology (2024)
Upadacitinib was more effective at achieving SFCR in UC at 52 weeks versus tofacitinib.
Keyphrases
  • ulcerative colitis
  • rheumatoid arthritis
  • clinical trial